Concentric Medical's modified neurovascular retriever:
This article was originally published in Clinica
Executive Summary
The Merci L6 Retriever, a device intended to restore blood flow in the neurovasculature by removing thrombi in patients experiencing ischaemic stroke, has received 510(k) clearance in the US. The product, developed by Concentric Medical, of Mountain View, California, is indicated for use in patients who are ineligible for, or unresponsive to, treatment with intravenous tissue plasminogen activator - clot-dissolving therapy. It may also be used in the retrieval of foreign bodies misplaced during interventional radiological procedures in the neurovasculature or the peripheral or coronary vasculature. The Merci L6 Retriever is a shaped Nitinol wire which can be delivered using standard catheterisation techniques, whereby a small puncture in the groin is used to introduce the retriever into an artery leading to the brain. Upon reaching the targeted area, the Merci retriever is deployed and returns to its original shape. The device incorporates a 2.7mm cylindrical helix with attached filaments; these provide an additional mechanism for securing the clot during retrieval.
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.